Biologics and ConjugatesJul 30, 2026
Antibody-Oligonucleotide Conjugates: From Conjugation Strategy to Purification and Analytical Control
Antibody-Oligo Conjugate (AOC), as an innovative targeted gene therapy biopharmaceutical, effectively integrates the targeting advantages of monoclonal antibodies and the gene regulatory functions of oligonucleotides, helping address key limitations in the inherent of traditional antibody drugs and nucleic acid drugs, and showing substantial clinical
Biologics and ConjugatesJun 25, 2026
FAQ: CMC Development Strategy for Oligonucleotides in AOCs
•How to reduce hydrolysis during SMCC conjugation? •Can SMCC conjugate after hydrolytic ring-opening? •How is OAR1 regulated during random SMCC conjugation? •Which strategy is preferred for siRNA linker conjugation: pre-annealing or post-annealing conjugation?
Biologics and ConjugatesJun 12, 2026
Biocatalysis Enables The Efficient Synthesis and Commercial Application of Unnatural Amino Acids (UAAs)
Biocatalysis is a pivotal enabler for the sustainable synthesis of unnatural amino acids. By integrating novel enzymes discovery, multi-enzyme cascades and chemo-enzymatic routes, Porton has established practical capabilities to address industry challenges in substrate specificity and enzyme stability. Moving forward, Porton remains dedicated to bridging the gap between laboratory innovation and industrial-scale application, providing customers with reliable, scalable and atom-efficient solutions for UAA production.
Biologics and ConjugatesMay 27, 2026
Dry Particle Coating for the Enhancement of API Flowability and Bulk Density
The mechanism of the dry particle coating and a short description of four coating techniques including comil, LabRAM, a high shear mixer and a jet mill are provided.
Biologics and ConjugatesMar 11, 2026
Optimization of Synthetic Process and Metal-Chelation Impurity Control Strategy for Complex Peptide-based RDCs
It fully demonstrates the strength of Porton's one-stop RDC service platform, excellent project management capabilities, and efficient production and operation.
Biologics and ConjugatesFeb 28, 2026
The Perfect Integration of Immobilized Enzymes and Flow Chemistry: A Powerful Booster for the Commercialization of Biocatalysis Technology
Adhering to Porton’s core value of “Pursuing Excellence”, Porton biocatalysis team has designated "enzyme immobilization technology and its industrialization" as a core strategic technology.
Biologics and ConjugatesJan 31, 2026
Process Simulation Platform: Enabling Process Development and Scale-up of Active Pharmaceutical Ingredients
Porton Crystallization team has the capability to perform process simulation of unit operations, including solvent swap, crystallization, filtration and drying.
Biologics and ConjugatesSep 24, 2025
Biocatalysis: A Powerful and Possible Greener Tool for Chemists in the Pharmaceutical Industry
End-to-end Enzyme Solutions Efficient Screening & process Development Comprehensive Quality Control Extensive Successful Applications Cases Technological Innovation Enabled Cost Savings
Biologics and ConjugatesApr 23, 2025
Challenges and Advances in CMC Process Development of BsADCs
Antibody drug conjugates (ADCs) have seen significant breakthroughs and reached numerous milestones since 2000 when the first ADC was approved by the FDA and have shown great promise for the treatment of cancer. First generation ADCs were designed to use the affinity of an antibody towards a specific cellular target to bring the cytotoxic payload to the tumor, for example. However, some level of off-target toxicity was often seen with many ADCs because other cellular interactions could occur prior to the payload physically reaching its intended target or the payload could cleave off. These events could lead to unintended death of non-cancerous cells.
